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Porphyromonas gingivalis a b s t r a c t
Arg-gingipain B (RgpB), a major virulence factor secreted by the periodontal pathogen Porphyro-
monas gingivalis is an Arg-speciﬁc cysteine proteinas e. By monitoring proteolytic cleavage of a
human salivary peptide histatin 5 using MALDI-TOF MS, RgpB puriﬁed from P. gingivalis HG66
was found to shift from a dominant Arg-X to dominant Lys-X activity, both in vitro and in vivo, upon 
reversible cysteine oxidation. Native PAGE analysis revealed the association of novel Lys-X activity 
with a reversible state change of the oxidized enzyme. The redox-reg ulated Lys-X activity of RgpB 
may provide a survival advanta ge to P. gingivalis against the oxidative host defence. 
Structured summary of protein interactions: 
RgpB cleaves histatin 5 by protease assay (View Interaction: 1, 2, 3, 4, 5, 6, 7)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. 1. Introduction C-terminall y truncated protein released into the culture ﬂuid [5–Porphyromon as gingivalis is an anaerobic, Gram-negative bacte- 
rium associate d with chronic periodontiti s, a destructive inﬂam-
matory disease of tooth supporting tissues. The pathogenicity of 
P. gingivalis has been attributed to a number of virulence factors, 
in particular the cell-associa ted and extracellul ar cysteine endo- 
proteinases including Arg-gingi pains (RgpA and RgpB) and Lys- 
gingipain (Kgp), which are known to be Arg-X speciﬁc and Lys-X 
speciﬁc, respectivel y. Gingipains contribute to around 85% of the 
proteolytic activity and 99% of the ‘‘trypsin-like’’ activity of the 
bacterium [1,2] and are capable of degrading a variety of host pro- 
teins and dysregulatin g host defenses [3]. The catalytic domains of 
the gingipains belong to the distinct cysteine proteinase family C25 
[4]. Gingipains are encoded by separate genes. The rgpB gene
encodes a calcium-s tabilized enzyme that exists as a 70–90 kDa 
outer membran e-associated protein as well as a discrete 50 kDa 8]. An isogenic mutant of P. gingivalis W50 with rgpB insertionally
inactivated was substantially less virulent than the wild type strain 
in murine lesion and periodonti tis models [9,10]. The virulence and 
Arg-X activity of the mutant was restored by complemen tation 
with a plasmid carrying rgpB [9]. RgpB was ﬁrst isolated from the 
culture ﬂuid of P. gingivalis HG66 by Chen et al. [5,6]. The crystal 
structure (PDB ID: 1CVR) of the C-terminall y truncated RgpB, from 
HG66, covalently bound with D-Phe-Phe-Arg- chloromethylketo ne 
(FFRCMK) inhibitor revealed a caspase-l ike catalytic domain [11].
All three gingipains require a reducing environment for full activity 
and are normally activated in vitro by pre-incubat ion with a thiol, 
in particular L-cysteine [5,7,12]. RgpB is classiﬁed as an Arg-X 
speciﬁc proteinase based on assay conditions that typically involve 
activation by 5–10 mM L-cysteine. During an autolysis study of 
puriﬁed RgpB from strain HG66 (unpublished), we discovered not 
only peptide fragments with a C-terminal Arg but also peptides 
with a C-terminal Lys. Using a human salivary peptide histatin 5
with three Arg and four Lys residues as substrate, we demonstrat e, 
for the ﬁrst time, novel Lys-X activity from RgpB. 
2. Materials and methods 
2.1. Bacterial strains, plasmids, and growth conditions 
P. gingivalis HG66 [13] was kindly provided by Prof Robert Pike 
(Monash University, Victoria, Australia ). P. gingivalis YH522KAB, in 
1276 Y.-Y. Chen et al. / FEBS Letters 587 (2013) 1275–1280which rgpA, rgpB, and kgp genes are disrupted with antibiotic 
resistance markers, and OPG37, a YH522KAB derivative bearing 
the shuttle plasmid pHY411, have been described previously 
[14]. P. gingivalis was maintain ed on blood agar and grown in batch 
culture anaerobical ly while Escherichia coli was grown at 37 C as 
described [14].
2.2. Cloning of rgpB and creation of P. gingivalis strain ERC129 
A 2.7-kb PCR-deri ved fragment, encompassing the rgpB coding
region and ﬂanking DNA generate d from P. gingivalis HG66 geno- 
mic DNA was ligated into pGEM -TEasy (Promega, Alexandria, 
NSW, Australia) as described in [9]. The rgpB gene was excised 
and inserted into the EcoRI site of pYH411 and fully sequenced. 
Puriﬁed recombinant plasmid DNA was electroporat ed into 
YH522KAB to create strain ECR129. 
2.3. RgpB puriﬁcation and characterization 
Cell-free culture ﬂuid prepared from a 2-day culture of P. gingi- 
valis HG66 was concentrated and resolved using a two-column 
procedure essentiall y as described [15]. Arg-X and Lys-X activities 
of column fractions were measured using Bz- L-Arg-pNA (L-BAPNA;
Sigma–Aldrich, St. Louis, MO) and Z- L-Lys-pNA (Novabiochem, 
Merck Millipore, Kilsyth, VIC, Australia), respectivel y. A sample of 
the protein fraction was ﬁrst made up to 360 ll, pre-incubated 
with 10 mM L-cysteine (Sigma) for 10 min by adding 40 ll of 
100 mM L-cysteine, pH 8.0, and then added with 2 mM substrate 
(400 ll) in 20 mM L-cysteine, pH 8.0, 400 mM Tris–HCl, pH 8.0, 
100 mM NaCl, and 30% (v/v) isopropanol . The initial rate of hydro- 
lysis was measured at 10 s intervals over 3 min at 410 nm in a
Hewlett Packard 8452A Diode Array spectrophot ometer (Agilent
Technologie s, Mulgrave, VIC, Australia). The results were expressed 
in units, where 1 U is equivalent to 1 lmol substrate hydrolyz ed 
per min at 37 C, pH 8.0. Protein concentratio ns were determined 
using Bradford assays (Bio-Rad, Gladesville, NSW, Australia) with 
BSA as standard. 
Puriﬁed RgpB was subjected to SDS–PAGE, Edman sequencing 
and MALDI-TOF MS as described [15]. For native PAGE, RgpB sam- 
ples (1 lg) before and after L-cysteine pre-incubation were diluted 
in 100 mM Tris–HCl, pH 8.8, 10% v/v glycerol, and 0.005% w/v 
bromophenol blue, immedia tely before electroph oresis in a Novex 
4–20% w/v Tris–Glycine gel (Invitrogen, Life Technologies, 
Mulgrave, VIC, Australia) in 25 mM Tris, 192 mM glycine, pH 8.3 
at 125 V at 4 C. BenchMar k Prestaine d Protein Ladder (Invitrogen)
was used for gel to gel comparis on. For free sulfhydryl group quan- 
titation, puriﬁed RgpB was mixed with Ellman’s reagent [16]
5,50-dithiobis(2-nitrobenzoic acid) (DTNB; Sigma), prepared in 
0.1 M Tris–HCl, pH 8.0 without or with guanidine hydrochloride 
(GuHCl), and incubate d for 15 min before 412 nm absorbance 
was recorded. DTNB and GuHCl was 240 lM and up to 6.8 M, 
respectively . L-Cysteine (6–40 lM) was concomitantly assayed 
under identical conditions to generate standard curves. 
2.4. In vitro and in vivo RgpB activity assays 
For the in vitro assay, puriﬁed RgpB was pre-incubat ed with 
1 mM L-cysteine at 1:40 mol/mol at 37 C. After 10, 20, and 
60 min, an aliquot of the enzyme was mixed with 20 volumes of 
10 lM histatin 5 (Sigma) in 10 mM NH 4HCO3 at 1:320 or 
1:8 mol/mol. An aliquot of the digest removed at various time 
points was acidiﬁed with formic acid (ﬁnal 1% v/v), mixed 1:1 
(v/v) with saturated a-cyano-4 -hydroxycinna mic acid matrix 
solution in aqueous 33% (v/v) acetonitrile and 1% (v/v) formic acid 
and analyzed by linear MALDI-TOF MS using a Voyager-DE mass 
spectromete r (AB Sciex, Mt Waverley, VIC, Australia ).For the in vivo assay, bacterial whole cells, harvested from late- 
exponenti al-phase batch cultures of P. gingivalis strains ECR129 
and OPG37 (negative control), were washed and maintained in 
TC150 buffer (20 mM Tris–HCl, pH 7.4, 5 mM CaCl 2 and 150 mM 
NaCl) at 4 C. After pre-incubation with L-cysteine at 37 C or being 
stored in a capped tube in TC150 without reducing agents for 24 h
at 4 C, bacterial cells (1.25  107) were mixed with 20 volumes of 
50 lM histatin 5. At various time points, an aliquot of the reaction 
mixture was clariﬁed by centrifugation. The resulting supernatant 
fraction was acidiﬁed, mixed with the matrix on a ground steel 
target (Bruker Daltonics, Preston, VIC, Australia ) and analyzed by 
reﬂectron MALDI-T OF MS using an Ultraﬂex TOF/TOF mass 
spectromete r (Bruker Daltonics). The identiﬁed peptide fragments 
were sequenced using LIFT (MS/MS) in the same instrument when 
required using default settings. 3. Results and discussion 
3.1. Puriﬁcation of soluble RgpB 
Typically, cell-free culture ﬂuid prepared from a 1-L culture of 
P. gingivalis HG66 exhibited 650–700 U Arg-X activity (L-BAPNA)
containing 10–13 U/mg protein. More than 90% of the activity 
was found in the soluble fraction (supernatant) after ultracentrifu -
gation (300000 g, 60 min, 4 C). Cell-free culture ﬂuid yielded 
60–70% recovery and 2-fold puriﬁcation of the Arg-X activity after 
19-fold concentration. The concentrate was ﬁrst resolved on a Q
Sepharos e HP column (Fig. 1A) that recovered at least 90% of both 
Arg-X and Lys-X (Z-L-Lys-pNA) activities. Six L-BAPNA-hydr olytic 
activity peaks were detected, including B1 (11% of the loaded 
activity), B2–B4 (66%), and B5–B6 (15%) while 99% of the loaded 
Z-L-Lys-pNA-hydrolytic activity was eluted in two peaks L1 and 
L2. Notably, L1 and L2 coincided with B5 and B6. Subsequent MS 
analysis of these peaks revealed the co-presence of Kgp and RgpA. 
Selected B2 peak fractions with no less than 70 U/mg were pooled 
and further resolved on Superose 12 (Fig. 1B). The pooled Superose 
12 fractions eluted between 12 and 14 ml exhibited 79 U/mg, a sin- 
gle band on SDS–PAGE (Fig. 2A) and a measured mass of 48.2 kDa 
using MALDI-TOF MS (Fig. 2B). Edman sequencing revealed the 
N-termin al 50-amino acid sequence that matched 100% with the 
RgpB of the same strain [6]. No minor sequence s, including Kgp, 
were detected. 3.2. Speciﬁcity change of puriﬁed RgpB 
RgpB is typically assayed after pre-incubat ion (activation) with 
L-cysteine (5–10 mM), prior to incubation with L-BAPNA chromo- 
genic substrate in L-cysteine-cont aining buffer. Although cysteine 
is the most abundan t low molecula r weight sulfhydryl compound 
in human plasma, its mean ‘‘total’’ concentration is only 0.26 mM 
[17–23]. Importan tly, the reported ‘‘total’’ cysteine concentr ation 
in plasma includes oxidized forms of cysteine, such as cystine 
and protein-S-S- Cys. In fact, the predominant form of ‘‘cysteine’’ 
in human plasma is cystine (>40 lM) and the reduced Cys is in 
the range of 8–10 lM [24–26]. Therefore, in this study a lower con- 
centration of L-cysteine (1 mM) was employed for ‘‘activation’ ’ and 
no additional L-cysteine was included in the substrate buffer to 
better reﬂect physiolog ical conditions. In addition, histatin 5, a
physiolog ically-relevant human host-derived salivary peptide, 
was used at low lM concentratio ns [27] as substrate . At a low 
enzyme:s ubstrate molar ratio (1:320), incomplete digestion of 
histatin 5 was achieved to estimate total RgpB activity by 
MALDI-T OF MS. RgpB showed differential speciﬁcity after pre- 
incubation with 1 mM L-cysteine for different time periods. After 
10-min pre-incubat ion, RgpB showed dominant Arg-X activity, 
Fig. 1. RgpB puriﬁcation. (A) Q Sepharose HP column chromatography of concen- 
trated P. gingivalis HG66 cell-free culture ﬂuid. (B) Superose 12 column chroma- 
tography of the B2 activity peak in panel A. 
Fig. 2. Analysis of puriﬁed RgpB by SDS–PAGE (A) and MALDI-TOF MS (B).
Fig. 3. Effect of L-cysteine pre-incubation on RgpB speciﬁcity in vitro. Puriﬁed RgpB 
was pre-incubated with 1 mM L-cysteine for 10 min (A), 20 min (B) or 60 min, (C)
before being added to histatin 5 (1:320 mol/mol) and incubated for 20 min, 60 min 
and 100 min, respectively. The digests were analyzed by linear MALDI-TOF MS. The 
identiﬁed histatin 5 fragments are numbered according to Table 1; those marked 
with an asterisk indicate Lys-X cleavage. More than one MS peaks marked with the 
same number indicate the presence of both singly- and multiply-charged ions of the 
same peptide. A minor peak indicated with an asterisk without numbering was 
identiﬁed as histatin 5-(1–10).
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(Fig. 3A). The Lys-X activity became stronger after 20-min 
(Fig. 3B) and 60 min (Fig. 3C) pre-incubat ion. As the Lys-X activity 
became dominan t, the total activity dropped based on the in- 
creased digestion time required for reducing the full-length hista- 
tin 5 to a similar level (see peptide 7, Fig. 3).
To avoid additional oxidation during prolonged digestion, a
higher enzyme:substr ate molar ratio (1:8) and a short, ﬁxed diges- 
tion time of 5 min were later employed. Under these conditions, an 
RgpB speciﬁcity change was again observed , from dominant Arg-X 
to dominant Lys-X (Fig. 4). To test whether the dominant Lys-X 
activity was derived from ‘‘oxidized ’’ RgpB, fresh 1 mM L-cysteine
was added to the same sample used in Fig. 4C, that instantly re- 
verted the enzyme back to dominant Arg-X activity (Fig. 4D).
Therefore, the novel speciﬁcity change was redox-re gulated. If complete ly cleaved at all three Arg residues (Arg6, Arg12, 
Arg22), only three histatin 5 fragments (peptides 1, 15 and 24)
would be detected (Table 1). Consistent with being an Arg-X en- 
zyme, these peptides were dominant in the digest with RgpB 
pre-incubat ed with 1 mM L-cysteine for 10 min or re-reduced with 
fresh L-cysteine (Fig. 4). Close examination revealed a minor Lys-X 
activity that produced peptides 23 and 28, likely resulted from 
minor cleavage of peptide 24 at Lys17 (Fig. 4A; Table 1). In con- 
trast, relatively oxidized RgpB, after 60-min pre-incubat ion with 
1 mM L-cysteine, exhibited strong Lys-X activity cleaving all four 
Lys (Lys5, Lys11, Lys13, Lys17) and weak Arg-X activity cleaving 
Arg12 and Arg6, but not Arg22, leading to a more complex diges- 
tion proﬁle with numerous MS peaks (Fig. 4C; Table 1). Interest- 
ingly, Arg12 and Arg6 are preceded by Lys while Arg22 is 
preceded by His. Importantly, oxidized RgpB cleaved Lys13 of hist- 
atin 5, that is preceded by Arg which is a non-cleavag e site for Kgp 
[28,29]. Consistently, leupeptin at 100 lM, which has no effect on 
Fig. 4. Reversible change of RgpB speciﬁcity in vitro. Puriﬁed RgpB was assayed as described (Fig. 3) except that histatin 5 was added at 1:8 mol/mol and digested for 5 min. 
An aliquot of the same RgpB enzyme used in panel C was re-reduced with fresh 1 mM L-cysteine immediately prior to addition of histatin 5 (D). The digests were analyzed as 
described (Fig. 3) and the results are summarized in Table 1. Peptide 8⁄, with the same m/z value as peptide 15, was also detected in panels B and C but not shown. 
Table 1
Predicted histatin 5 tryptic fragm ents with average MH + greater than 600 and those 
found experimentally in RgpB digestion of histatin 5 as shown in Fig. 4. Numb ered 
peptides marked with an asterisk indicate one or two Lys-X cleavages. 
No. Residue 
No. 
Amino acid sequence MH +(av.) Fig. 4
1 1–6 DSHAKR 713.8 A, B, C, D
2⁄ 1–11 DSHAKRHHGYK 1336.5 C
3 1–12 DSHAKRHHGYKR 1492.6 B, C
4⁄ 1–13 DSHAKRHHGYKRK 1620.8 C
5⁄ 1–17 DSHAKRHHGYKRKFHEK 2162.4 C
6 1–22 DSHAKRHHGYKRKFHEKHHSHR 2817.1 
7 1–24 DSHAKRHHGYKRKFHEKHHSHRGY 3037.3 C
8⁄ 6–11 RHHGYK 797.9 B, C
9⁄ 6–12 RHHGYKR 954.1 B, C
10 ⁄ 6–13 RHHGYKRK 1082.3 C
11 ⁄ 6–17 RHHGYKRKFHEK 1623.9 C
12 ⁄ 6–22 RHHGYKRKFHEKHHSHR 2278.6 
13 ⁄ 6–24 RHHGYKRKFHEKHHSHRGY 2498.8 C
14 ⁄ 7–11 HHGYK 641.7 
15 7–12 HHGYKR 797.9 A, B, C, D
16 ⁄ 7–13 HHGYKRK 926.1 
17 ⁄ 7–17 HHGYKRKFHEK 1467.7 C
18 7–22 HHGYKRKFHEKHHSHR 2122.4 
19 7–24 HHGYKRKFHEKHHSHRGY 2342.6 C
20 ⁄ 12–17 RKFHEK 845.0 C
21 ⁄ 12–22 RKFHEKHHSHR 1499.7 
22 ⁄ 12–24 RKFHEKHHSHRGY 1719.9 C
23 ⁄ 13–17 KFHEK 688.8 
24 13–22 KFHEKHHSHR 1343.5 A, B, D
25 13–24 KFHEKHHSHRGY 1563.7 B, C
26 ⁄ 14–22 FHEKHHSHR 1215.3 B
27 ⁄ 14–24 FHEKHHSHRGY 1435.6 B, C
28 ⁄ 18–22 HHSHR 673.7 A, B, D
29 ⁄ 18–24 HHSHRGY 893.9 B, C
Fig. 5. Reversible change of RgpB redox states revealed by native PAGE. Puriﬁed
RgpB was analyzed on a native Tris–glycine gel before (lane 1, Ori.) and after 
incubation with 1 mM L-cysteine for 10 min (lane 2), 20 min (lane 3), and 60 min 
(lane 4). An aliquot of the same sample used in lane 4 was re-reduced with fresh 
1 mM L-cysteine immediately prior to gel analysis (lane 5). For comparison, puriﬁed
RgpB was incubated with 10 mM L-cysteine for 10 min (lane 6) and 60 min (lane 7),
both of which showed dominant Arg-X activity. 
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RgpB.
3.3. Association of a reversible state change of RgpB with novel Lys-X 
activity
Upon native PAGE, the RgpB form that exhibited mixed Arg-X 
and Lys-X activity showed four bands b1–b4 (Fig. 5, lane 1), with b3 and b2 being dominant. After 10-min incubation with 1 mM 
L-cysteine (1:40 mol/mol), the four bands were transformed into 
one, correspondi ng to b2 (lane 2). As the incubation time increased, 
a band correspondi ng to b4 appeared after 20 min (lane 3) and an- 
other band correspondi ng to b3 became visible after 60 min (lane
4). When fresh 1 mM L-cysteine was added to the same sample 
used for lane 4, only one band corresponding to b2 was observed 
(lane 5), indicating the association of multiple redox-regul ated, 
reversibl e forms of RgpB with reversible speciﬁcity change. In com- 
parison, when RgpB was incubate d with 10 mM L-cysteine
(1:400 mol/mol), only one band correspondi ng to b2 was detected 
after 10-min or 60-min incubation (lanes 6–7), consistent with 
unaltered dominant Arg-X activities. Further free thiol analysis 
Fig. 6. Ribbon diagram of the crystal structure of RgpB reproduced from PDB ID: 
1CVR [11] using PyMOL. Catalytic domain: subdomains A (blue) and B (green);
immunoglobin superfamily domain (red); Sc atoms of seven cysteine residues 
(yellow); Zn 2+ (dark grey); Ca 2+ (light grey); FFRCMK inhibitor (pink and blue sticks)
covalently attached to the catalytic Cys244. 
Fig. 7. Reversible change of RgpB speciﬁcity in vivo. Freshly-prepared strain 
ECR129 cells were pre-incubated with 1 mM L-cysteine for 60 min (A), oxidized for 
24 h (B) or re-reduced after 24 h oxidation (C). Treated cells were added to histatin 
5 for 5 min and the resulting supernatant fractions were analyzed using reﬂectron
MALDI-TOF MS. The identiﬁed histatin 5 fragments were labelled as described in 
Fig. 3.
Y.-Y. Chen et al. / FEBS Letters 587 (2013) 1275–1280 1279revealed that RgpB with mixed Lys-X and Arg-X activity (Fig. 5,
lane 1) contained 0.8 mol and 1.7 mol free thiols per mol enzyme 
in the absence and presence of 4.8 M GuHCl, respectively , at room 
temperature . The detectab le free thiols increased signiﬁcantly to 
3.2 mol per mol enzyme when assayed at 37 C with 6.8 M GuHCl. 
As RgpB has 7 Cys residues (Fig. 6), the above data support its oxi- 
dative susceptibility via cysteine residues, creating multiple 
reversible oxidative states responsib le for reversible speciﬁcity
change.
3.4. Reversible speciﬁcity change of cell-assoc iated RgpB 
P. gingivalis mutant strain ECR129 expressing recombinant RgpB 
derived from strain HG66 as the only gingipain was created in a tri- 
ple gingipain mutant strain background YH522KAB. Freshly-pre- 
pared ECR129 cells exhibited dominant Arg-X activity even after 
60-min pre-incubat ion with 1 mM L-cysteine (Fig. 7A). Under these 
conditions puriﬁed RgpB exhibited dominant Lys-X activity 
(Fig. 4C). This difference was attributed to prolonge d air exposure 
of RgpB during puriﬁcation as compare d to whole cells freshly har- 
vested from an anaerobic culture supplem ented with 5 mg/ml L-
cysteine (28 mM). To demonst rate the effect of oxidation on RgpB 
speciﬁcity in vivo, washed ECR129 cells were air-oxidi zed by incu- 
bation in Tris buffer without reducing agents for 24 h at 4 C,
resulting in mixed Arg-X and Lys-X activity (Fig. 7B). Pre-incuba- 
tion of the oxidized cells with fresh L-cysteine reverted the speci- 
ﬁcity back to dominant Arg-X (Fig. 7C), consisten t with the 
in vitro results. 
4. Conclusion 
Reversible redox-regul ated speciﬁcity change of P. gingivalis 
HG66 RgpB occurs both in vitro and in vivo as a soluble or cell- 
associated enzyme, respectivel y. The novel Lys-X activity was dis- 
tinct from Kgp activity as it was (1) demonst rated with puriﬁed
RgpB and a P. gingivalis mutant expressing RgpB as the sole gingi- 
pain, (2) activated by reversible oxidation, (3) inhibited by leupep- 
tin, and (4) active towards a non-cleavag e site for Kgp (Arg-Lys-X).
This redox regulated Lys-X activity of RgpB may provide a survival 
advantage against the oxidative host defence and may help explain why Na-p-tosyl-L-lysine-chlorom ethyl ketone (TLCK) with a P1 
lysine is a known inhibitor of the enzyme [1].
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